Spotting Alzheimer’s early with a simple blood test
The early detection of Alzheimer’s disease remains one of the most pressing challenges in modern neurology. With current approaches relying on expensive imaging techniques or invasive cerebrospinal fluid analysis, patients frequently end up being diagnosed at advanced stages, where treatment has limited effectiveness. The EU-funded 2D-BioPAD(opens in new window) project is addressing this critical gap by developing a point-of-care diagnostic tool that enables early detection through a simple, far less invasive blood test.
Graphene-based tech
The device relies on a sophisticated electrochemical biosensor constructed from graphene, a 2D material renowned for its exceptional strength and conductivity. By incorporating specific aptamers – synthetic molecules engineered to bind precisely to target proteins – the tool can simultaneously identify several biomarkers with a tiny drop of blood. This makes it possible to detect disease indicators at far lower concentrations than conventional methods. Designed for use outside specialised hospitals, the system allows diagnosis to be made by general practitioners and at community health centres. The purpose is not to replace brain scans and spinal taps but to make earlier screening – and therefore earlier detection – possible, before symptoms appear and when treatments are more effective. “There are good reasons for knowing you may go on to develop dementia,” comments Vincent Bouchiat, CEO and co-founder of French 2D-BioPAD project partner Grapheal, in an article(opens in new window) published on the website of ‘Horizon, The EU Research & Innovation Magazine’. “New Alzheimer’s medications show promise in delaying the progression of the disease, which is obviously a huge step forward.”
An AI helping hand
A defining feature of the 2D-BioPAD approach is its strategic integration of AI to overcome traditional limitations in biosensor development. The project is using machine learning not only for data analysis but also as a fundamental tool in the biosensor design phase. AI is being used to identify aptamer sequences for specific biomarker targets to help speed up aptamer selection, narrow down the pool of aptamer candidates and predict how well specific aptamers will function in the graphene-based device. AI models are also being used to explore improvements in the manufacturing of the biosensor. The initial focus will be on optimising its functionalisation using publicly available data and input from technology partners, with the potential to also improve sensitivity, defect levels and conductivity. The advantages of the 2D-BioPAD tool are several. Firstly, and most importantly, the graphene sensor’s high sensitivity ensures that the disease can be detected before significant cognitive decline occurs, opening a critical window for treatment to take place when it could make a real difference. The minimally invasive nature of the blood test also reduces patient anxiety and discomfort. By being portable and easy to use, the device transforms Alzheimer’s screening from a complex, hospital-based procedure into a routine part of primary care, reducing the burden on healthcare systems and likely significantly lowering diagnostic costs. “Early detection will only be realistic for people when it’s inexpensive for the health service, and painless and simple for the patient,” states Aristeidis Bakandritsos, a senior researcher at the Czech Advanced Technology and Research Institute, which is part of project coordinator Palacký University Olomouc in Czechia. With pilot studies underway in Germany, Greece and Finland, 2D-BioPAD (Supple Graphene Bio-Platform for point-of-care early detection and monitoring of Alzheimer’s Disease) promises to redefine the landscape of Alzheimer’s diagnosis, offering hope for earlier intervention and improved patient outcomes. For more information, please see: 2D-BioPAD project website(opens in new window)
